Pharmsynthez

LIFE

RU000A0JR514

Pharmaceuticals

End-of-day quote Moscow Micex - RTS Other stock markets 03:30:00 08/07/2022 am IST			5-day change	1st Jan Change
4.505 ^RUB	+10.15%		-.--%	-.--%

2023	Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt	CI
2023	Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2022	CI

AS Kevelt announced that it expects to receive €2.2 million in funding from Open Joint-Stock Company Pharmsynthez.

July 03, 2015

AS Kevelt announced that it will receive €2.2 million in its equity round of funding from existing investor, Open Joint-Stock Company Pharmsynthez on July 3, 2015. The transaction has been approved by the shareholders of the investor.

Latest news about Pharmsynthez

Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt	19/23/19	CI
Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Full Year Ended December 31, 2022	19/23/19	CI
Public Joint-Stock Company "Pharmsynthez" announced that it expects to receive funding from Central Bank of the Russian Federation	08/22/08	CI
Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt	28/22/28	CI
Public Joint-Stock Company "Pharmsynthez" Reports Earnings Results for the Half Year Ended June 30, 2021	12/21/12	CI
Xenetic Biosciences, Inc. Enters into Amendment Number One to Master Services Agreement with PJSC Pharmsynthez	16/21/16	CI
Market Chatter: South Korean Regulator Rejects Thelma Therapeutics's Phase Three Trial for COVID-19 Cure	14/21/14	MT
Public Joint-Stock Company Pharmsynthez Reports Earnings Results for the Full Year Ended December 31, 2018	02/21/02	CI
PJSC Pharmsynthez Starts the Registration Phase of Epolong	16/21/16	CI
HiFiBiO Therapeutics Inks Partnership with Pharmsynthez and IBCh for the Clinical Development and Commercialization of its SARS-CoV-2 Neutralizing Antibody in Russia	23/20/23	CI
Public Joint-Stock Company "Pharmsynthez" acquired remaining unknown minority stake in VAKTSINY.	19/20/19	CI
Xenetic Biosciences, Inc. and PJSC Pharmsynthez Enters into Master Service Agreement to Advance the Development of Xcart Technology	16/20/16	CI
Public Joint-Stock Company "Pharmsynthez" Auditor Raises 'Going Concern' Doubt	27/18/27	CI
Pharmsynthez Appoints Members of Audit Commission	06/18/06	CI
Rusnano To Sell Its Stake In Pharmsynthez	25/17/25	CI
Public Joint-Stock Company Pharmsynthez announced that it has received RUB 3.80 billion in funding	28/16/28	CI
Pharmsynthez Reports Earnings Results for the Six Months of 2016	29/16/29	CI
OJSC Pharmsynthez Reports Earnings Results for the Six Months Ended June 30, 2016	15/16/15	CI
PJSC Pharmsynthez Announces Earnings Results for the First Quarter of 2016	16/16/16	CI
Xenetic Biosciences, Inc. announced that it has received $3.5 million in funding from Public Joint-Stock Company Pharmsynthez	31/16/31	CI
Xenetic Biosciences, Inc. announced that it expects to receive $3.5 million in funding from Open Joint-Stock Company Pharmsynthez.	13/15/13	CI
Pharmsynthez to Invest RUB 1.3 Billion in Bratsk Facility	22/15/22	CI
OJSC Pharmsynthez Announces Earnings Results for the First Half of 2015	31/15/31	CI
Pharmsynthez to Open Factory in Bratsk in 2017	28/15/28	CI
AS Kevelt announced that it expects to receive €2.2 million in funding from Open Joint-Stock Company Pharmsynthez.	03/15/03	CI

Chart Pharmsynthez

Duration

Period

More charts

Company Profile

Farmsintez PAO (Farmsintez OJSC) is a Russia-based company, which is engaged in the pharmaceutical sector. The Company focuses on the medical research, development and manufacture of drugs ingredients used in oncology, gynecology, tuberculosis therapy and others. In addition, Farmsintez OAO offers chemical research services, chemical technology development and quality control services. The Company sells its products domestically, as well as abroad, including the Commonwealth of Independence State (CIS) countries. It has two wholly owned subsidiaries located in Moscow and Tallin, Estonia. As of May 21, 2011, the Companyâs major shareholder was EphaG AS with a stake of 69.23%. In April 2013, the Company acquired the pharmacies of Guardum Pharmaceuticals in the U.S. state of Florida.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARMSYNTHEZ	-.--%	15M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B